This invention relates to selective m1 muscarinic agonist, their use or a
formulation thereof in the treatment of glaucoma and/or other conditions
which are related to elevated intraocular pressure in the eye of a
patient. This invention also relates to the use of such compounds to
provide a neuroprotective effect to the eye of mammalian species,
particularly humans. In addition, the present invention relates to the
use of the compounds in the treatment of dementia such as Alzheimer's
disease and vascular dementia, depression, attention deficit disorder,
sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and
atony of gastrointestinal tract.
